Showing results (101-110 of 108) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 108 results.
Annals of Hematology|March 25, 2014
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IVUlrike Proetel, Nadine Pletsch, Michael Lauseker, et al.
Annals of Hematology|October 29, 2013
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IVLida Kalmanti, Susanne Saussele, Michael Lauseker, et al.
Swiss Medical Weekly|March 2, 2018
Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016Jakob R Passweg, Helen Baldomero, Marc Ansari, et al.
Blood|May 25, 2006
Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow TransplantationRodrigo Martino, Rocio Parody, Takahiro Fukuda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2013
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IVRüdiger Hehlmann, Martin C Müller, Michael Lauseker, et al.
Blood|April 29, 2015
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IVSusanne Saussele, Marie-Paloma Krauss, Rüdiger Hehlmann, et al.
Cancers|February 10, 2021
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDSJeroen Janssen, Bob Löwenberg, Markus Manz, et al.
Haematologica|December 6, 2018
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IVChristian Michel, Andreas Burchert, Andreas Hochhaus, et al.
Pageof 11